A Treatment for Gastroesophageal Reflux Disease
HK inno.N announced that its gastroesophageal reflux disease treatment K-CAB Tab has been approved by the Health Sciences Authority of Singapore on Jan. 11.
According to approval documents, the drug has four approved indications – the treatment of erosive gastroesophageal reflux diseases, the treatment of non-erosive gastroesophageal reflux diseases, the treatment of gastric ulcer and combination therapy with antibiotics for the eradication of Helicobacter pylori in patients with peptic ulcer or chronic atrophic gastritis.
The treatment will be sold under the name of K-CAB in Singapore. HK inno.N is planning to release it in Singapore within this year. The Korean drugmaker signed an export contract with UITC, a partner in Singapore, in 2020.
HK inno.N is ready to penetrate the Southeast Asian market in earnest as it has obtained approval from Indonesia, the largest market in Southeast Asia, the Philippines and Singapore.